Quantbot Technologies LP Sells 16,778 Shares of Qiagen N.V. $QGEN

Quantbot Technologies LP cut its stake in shares of Qiagen N.V. (NYSE:QGEN) by 79.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,350 shares of the company’s stock after selling 16,778 shares during the period. Quantbot Technologies LP’s holdings in Qiagen were worth $194,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Smartleaf Asset Management LLC increased its stake in shares of Qiagen by 1,383.3% during the third quarter. Smartleaf Asset Management LLC now owns 890 shares of the company’s stock worth $39,000 after purchasing an additional 830 shares during the period. MAI Capital Management boosted its stake in Qiagen by 998.9% in the 2nd quarter. MAI Capital Management now owns 978 shares of the company’s stock valued at $47,000 after purchasing an additional 889 shares during the period. Allworth Financial LP grew its holdings in Qiagen by 260.1% in the 2nd quarter. Allworth Financial LP now owns 1,102 shares of the company’s stock valued at $53,000 after buying an additional 796 shares in the last quarter. GAMMA Investing LLC increased its position in Qiagen by 375.5% during the 3rd quarter. GAMMA Investing LLC now owns 1,241 shares of the company’s stock worth $55,000 after buying an additional 980 shares during the period. Finally, Jones Financial Companies Lllp increased its position in Qiagen by 64.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 1,610 shares of the company’s stock worth $71,000 after buying an additional 628 shares during the period. Institutional investors and hedge funds own 70.00% of the company’s stock.

Qiagen Stock Down 4.3%

Shares of QGEN opened at $41.15 on Thursday. The firm has a 50 day simple moving average of $49.58 and a two-hundred day simple moving average of $48.99. The company has a debt-to-equity ratio of 0.44, a current ratio of 3.90 and a quick ratio of 3.31. Qiagen N.V. has a one year low of $40.14 and a one year high of $57.81. The company has a market cap of $8.69 billion, a P/E ratio of 20.41, a P/E/G ratio of 2.10 and a beta of 0.70.

Qiagen (NYSE:QGEN) last issued its earnings results on Thursday, February 5th. The company reported $0.62 earnings per share for the quarter, beating analysts’ consensus estimates of $0.61 by $0.01. Qiagen had a return on equity of 14.56% and a net margin of 20.33%.The firm had revenue of $540.42 million for the quarter, compared to the consensus estimate of $528.53 million. During the same quarter last year, the business posted $0.61 EPS. The company’s revenue was up 3.6% compared to the same quarter last year. Research analysts forecast that Qiagen N.V. will post 2.26 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on QGEN. Weiss Ratings reissued a “hold (c)” rating on shares of Qiagen in a research report on Monday, December 29th. Stifel Nicolaus set a $50.00 price objective on shares of Qiagen and gave the stock a “hold” rating in a research note on Friday, February 6th. JPMorgan Chase & Co. lifted their price objective on shares of Qiagen from $55.00 to $60.00 and gave the stock an “overweight” rating in a research note on Friday, February 6th. Deutsche Bank Aktiengesellschaft lowered shares of Qiagen from a “buy” rating to a “hold” rating and increased their target price for the stock from $52.00 to $54.00 in a research report on Thursday, January 22nd. Finally, Wall Street Zen raised shares of Qiagen from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Four analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $55.20.

Qiagen Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.